Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 570

1.

GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains.

Saxena GK, Theocharopoulos I, Aziz NT, Jones M, Gnanapavan S, Giovannoni G, Schmierer K, Garnett JA, Baker D, Kang AS.

Sci Rep. 2020 Feb 5;10(1):1860. doi: 10.1038/s41598-020-58041-3.

2.

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.

Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S; MS-SMART Investigators.

Lancet Neurol. 2020 Jan 22. pii: S1474-4422(19)30485-5. doi: 10.1016/S1474-4422(19)30485-5. [Epub ahead of print]

3.

Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk.

Dobson R, Jitlal M, Marshall CR, Noyce AJ, Robson J, Cuzick J, Giovannoni G.

Ann Neurol. 2020 Jan 23. doi: 10.1002/ana.25688. [Epub ahead of print]

PMID:
31975487
4.

World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.

McDonell J, Costello K, Laurson-Doube J, Rijke N, Giovannoni G, Banwell B, Baneke P.

Mult Scler. 2020 Feb;26(2):153-158. doi: 10.1177/1352458519898340. Epub 2020 Jan 16.

PMID:
31944872
5.

BMI and low vitamin D are causal factors for multiple sclerosis: A Mendelian Randomization study.

Jacobs BM, Noyce AJ, Giovannoni G, Dobson R.

Neurol Neuroimmunol Neuroinflamm. 2020 Jan 14;7(2). pii: e662. doi: 10.1212/NXI.0000000000000662. Print 2020 Mar.

6.

The potential of neurofilaments analysis using dry-blood and plasma spots.

Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A.

Sci Rep. 2020 Jan 9;10(1):97. doi: 10.1038/s41598-019-54310-y.

7.

Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.

Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MJ.

Trends Mol Med. 2019 Dec 17. pii: S1471-4914(19)30294-1. doi: 10.1016/j.molmed.2019.11.003. [Epub ahead of print] Review.

8.

Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme.

Giovannoni G, Brex PA, Dhiraj D, Fullarton J, Freddi M, Rodgers-Gray B, Schmierer K.

Mult Scler J Exp Transl Clin. 2019 Dec 5;5(4):2055217319893103. doi: 10.1177/2055217319893103. eCollection 2019 Oct-Dec.

9.

Theme 7 Pre-clinical therapeutic strategies.

Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(sup1):217-245. doi: 10.1080/21678421.2019.1646995.

PMID:
31702471
10.

Grassroot efforts towards diversity in MS care and research: Win-win for patients and science.

Waubant E, Levy M, Lechner-Scott J, Giovannoni G, Hawkes C.

Mult Scler Relat Disord. 2019 Oct;35:A1-A2. doi: 10.1016/j.msard.2019.101428. Epub 2019 Oct 2. No abstract available.

PMID:
31679745
11.

Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis.

Baker D, Pryce G, James LK, Schmierer K, Giovannoni G.

Eur J Neurol. 2020 Feb;27(2):221-228. doi: 10.1111/ene.14105. Epub 2019 Nov 6. Review.

PMID:
31617269
12.

Multiple sclerosis and migration revisited.

Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Waubant E (Chief editors).

Mult Scler Relat Disord. 2019 Sep;34:A1-A2. doi: 10.1016/j.msard.2019.08.001. Epub 2019 Aug 1. No abstract available.

PMID:
31543261
13.

Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care.

Oreja-Guevara C, Potra S, Bauer B, Centonze D, Giambastiani MP, Giovannoni G, Kesselring J, Langdon D, Morrow SA, Nouvet-Gire J, Pontaga M, Rieckmann P, Schippling S, Alexandri N, Shanahan J, Thompson H, Van Galen P, Vermersch P, Yeandle D.

Adv Ther. 2019 Nov;36(11):3238-3252. doi: 10.1007/s12325-019-01071-9. Epub 2019 Sep 5.

14.

The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect.

Hasan H, Burrows M, Athauda DS, Hellman B, James B, Warner T, Foltynie T, Giovannoni G, Lees AJ, Noyce AJ.

Mov Disord Clin Pract. 2019 Jun 25;6(6):462-469. doi: 10.1002/mdc3.12798. eCollection 2019 Jul.

PMID:
31392247
15.

Do we have equipoise when it comes to how we treat active multiple sclerosis?

Giovannoni G.

Lancet Neurol. 2019 Oct;18(10):909-911. doi: 10.1016/S1474-4422(19)30227-3. Epub 2019 Jul 30. No abstract available.

PMID:
31375367
16.

Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.

Pardo S, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E, Levy M.

Mult Scler Relat Disord. 2019 Aug;33:A1-A2. doi: 10.1016/j.msard.2019.07.001. Epub 2019 Jul 2. No abstract available.

PMID:
31324299
17.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators.

Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.

PMID:
31285147
18.

Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis.

Baker D, Jacobs BM, Gnanapavan S, Schmierer K, Giovannoni G.

Mult Scler Relat Disord. 2019 Oct;35:19-25. doi: 10.1016/j.msard.2019.06.030. Epub 2019 Jun 26. Review.

PMID:
31279232
19.

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers.

Stuve O, Soelberg Soerensen P, Leist T, Giovannoni G, Hyvert Y, Damian D, Dangond F, Boschert U.

Ther Adv Neurol Disord. 2019 Jun 18;12:1756286419854986. doi: 10.1177/1756286419854986. eCollection 2019.

20.

One size doesn't fit all.

Lechner-Scott J, Giovannoni G, Hawkes C, Levy M, Waubant E.

Mult Scler Relat Disord. 2019 Jun;31:A1-A2. doi: 10.1016/j.msard.2019.04.034. Epub 2019 Apr 30. No abstract available.

PMID:
31159999
21.

Screening performance of abbreviated versions of the UPSIT smell test.

Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE, Noyce AJ.

J Neurol. 2019 Aug;266(8):1897-1906. doi: 10.1007/s00415-019-09340-x. Epub 2019 May 3.

22.

Survival: the ultimate long-term outcome in multiple sclerosis.

Giovannoni G.

Brain. 2019 May 1;142(5):1166-1167. doi: 10.1093/brain/awz101. No abstract available.

PMID:
31032846
23.

Three suggestions to decrease the financial burden of MS treatments.

Waubant E, Giovannoni G, Hawkes C, Lechner-Scott J, Levy M.

Mult Scler Relat Disord. 2019 May;30:A1. doi: 10.1016/j.msard.2019.03.023. No abstract available.

PMID:
30987755
24.

Chronic-relapsing varicella zoster meningitis - Successfully treated with varicella vaccine.

Gaiottino J, Giovannoni G, Breuer J, Tang JW.

J Infect. 2019 Jul;79(1):61-74. doi: 10.1016/j.jinf.2019.04.009. Epub 2019 Apr 10. No abstract available.

PMID:
30980839
25.

Visibility and representation of women in multiple sclerosis research.

Thomson A, Horne R, Chung C, Marta M, Giovannoni G, Palace J, Dobson R.

Neurology. 2019 Apr 9;92(15):713-719. doi: 10.1212/WNL.0000000000007276. Epub 2019 Mar 20. Review.

26.

Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease.

Levy M, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E.

Mult Scler Relat Disord. 2019 Apr;29:A1-A2. doi: 10.1016/j.msard.2019.03.007. No abstract available. Erratum in: Mult Scler Relat Disord. 2019 Jul;32:138.

PMID:
30885376
27.

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.

Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.

Mult Scler Relat Disord. 2019 Apr;29:168-174. doi: 10.1016/j.msard.2019.01.038. Epub 2019 Jan 24.

28.

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.

Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.

Mult Scler Relat Disord. 2019 Apr;29:157-167. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20.

29.

Multiple Sclerosis and Vitamin D - Caviar or a Dog's Dinner?

Hawkes C, Giovannoni G, Lechner-Scott J, Levy M, Waubant E.

Mult Scler Relat Disord. 2019 Feb;28:A1-A2. doi: 10.1016/j.msard.2019.02.015. No abstract available.

PMID:
30823982
30.

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.

Axelsson M, Dubuisson N, Novakova L, Malmeström C, Giovannoni G, Lycke J, Gnanapavan S.

Acta Neurol Scand. 2019 May;139(5):422-427. doi: 10.1111/ane.13069. Epub 2019 Mar 5.

PMID:
30657162
31.

Should our treatment target in MS include the intrathecal plasma cell response?

Giovannoni G, Hawkes C, Levy M, Lechner-Scott J, Waubant E.

Mult Scler Relat Disord. 2019 Jan;27:A1-A2. doi: 10.1016/j.msard.2018.12.039. No abstract available.

PMID:
30642567
32.

UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines.

Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA.

Pract Neurol. 2019 Apr;19(2):106-114. doi: 10.1136/practneurol-2018-002060. Epub 2019 Jan 5. Review.

PMID:
30612100
33.

Is the 'MS establishment' biased; the case for addressing gender inequality in the field of MS?

Giovannoni G.

Mult Scler Relat Disord. 2019 Feb;28:153-154. doi: 10.1016/j.msard.2018.12.020. Epub 2018 Dec 20. No abstract available.

PMID:
30594816
34.

Vaccines and disease-modifying treatments.

Waubant E, Giovannoni G, Hawkes C, Levy M.

Mult Scler Relat Disord. 2018 Nov;26:A1-A2. doi: 10.1016/j.msard.2018.10.017. Epub 2018 Oct 24. No abstract available.

PMID:
30573174
35.

Social capital: Implications for neurology.

Reyes S, Giovannoni G, Thomson A.

Brain Behav. 2019 Jan;9(1):e01169. doi: 10.1002/brb3.1169. Epub 2018 Dec 8. Review.

36.

Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP, Marta M, Gnanapavan S, Espasandin M, Mathews J, Giovannoni G, Baker D, Schmierer K.

Mult Scler Relat Disord. 2019 Jan;27:247-253. doi: 10.1016/j.msard.2018.11.001. Epub 2018 Nov 2.

PMID:
30419510
37.

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.

Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G.

Mult Scler. 2018 Dec;24(14):1862-1870. doi: 10.1177/1352458518808189. Epub 2018 Nov 12.

38.

Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier.

Yeandle D, Rieckmann P, Giovannoni G, Alexandri N, Langdon D.

Neurol Ther. 2018 Dec;7(2):179-187. doi: 10.1007/s40120-018-0118-8. Epub 2018 Nov 9.

39.

The unintended consequences of NICE.

Giovannoni G.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):247-248. doi: 10.1136/jnnp-2018-318866. Epub 2018 Nov 2. No abstract available.

PMID:
30389780
40.

Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica.

Levy M, Giovannoni G, Hawkes C, Waubant E.

Mult Scler Relat Disord. 2018 Oct;25:A1-A2. doi: 10.1016/j.msard.2018.09.027. No abstract available.

PMID:
30384960
41.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2019 Nov;25(13):1809-1818. doi: 10.1177/1352458518809326. Epub 2018 Nov 1.

42.

The Multiple Sclerosis Care Unit.

Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G.

Mult Scler. 2019 Apr;25(5):627-636. doi: 10.1177/1352458518807082. Epub 2018 Oct 23.

43.

Learning ability correlates with brain atrophy and disability progression in RRMS.

Sormani MP, De Stefano N, Giovannoni G, Langdon D, Piani-Meier D, Haering DA, Kappos L, Tomic D.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):38-43. doi: 10.1136/jnnp-2018-319129. Epub 2018 Oct 15.

44.

Inclusion criteria used in trials of people with progressive multiple sclerosis.

Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G.

Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769. [Epub ahead of print] No abstract available.

PMID:
30318994
45.

Multiple sclerosis - a review.

Dobson R, Giovannoni G.

Eur J Neurol. 2019 Jan;26(1):27-40. doi: 10.1111/ene.13819. Epub 2018 Nov 18. Review.

PMID:
30300457
46.

e-Health and multiple sclerosis: An update.

Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S.

Mult Scler. 2018 Nov;24(13):1657-1664. doi: 10.1177/1352458518799629. Epub 2018 Sep 19. Review.

PMID:
30231004
47.

Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis.

Baker D, Pryce G, Amor S, Giovannoni G, Schmierer K.

Brain. 2018 Oct 1;141(10):2834-2847. doi: 10.1093/brain/awy239. Review.

PMID:
30212896
48.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

49.

Editors' Welcome.

Hawkes CH, Giovannoni G, Levy M, Waubant E.

Mult Scler Relat Disord. 2018 Aug;24:A1-A2. doi: 10.1016/j.msard.2018.08.010. No abstract available.

PMID:
30190056
50.

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network.

BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944.

Supplemental Content

Loading ...
Support Center